At Urovant Sciences, we’ve made it our mission to keep patient health and well-being front and center. In accordance with Urovant’s ongoing research and development efforts, our Medical Affairs team is honored to play a vital role by providing scientific support and to prioritize the resources needed to assist you where and when it matters most for patients.
Overactive Bladder (OAB) is a symptom complex that, while generally not life-threatening, can greatly impact quality of life.
Discover Our Pipeline
Urovant Sciences is currently studying vibegron for an additional indication. Separately, the company initiated a Phase 2 study of a novel gene therapy.
* Estimates are based on 23% prevalence rate from the EpiLUTS study and 2018 US Census Bureau population number projections for 2018.
1. Coyne KS, Sexton CC, Vats V, Thompson C, Kopp ZS, Milsom I. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011;77(5):1081–1087.
2. US Census Bureau. Age and Sex Composition: 2018. Available at: https://data.census.gov/cedsci/table?q=people%20by%20age%20group&t=Age%20and%20 Sex&tid=ACSST1Y2018.S0101&hidePreview=false. Accessed November 4, 2020.
3. Puckrein G, Walker D, Xu L, Congdon P, Gooch K. The prevalence and forecast prevalence of overactive bladder in the Medicare population. Clin Med Insights Urol. 2019;12. doi:10.1177/1179561119847464